Evommune, Inc. (EVMN) Stock
Fundamentals
Source: third-party data provider, as of October 12, 2026
Compare with EVMN
Recent news

Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress
Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress
EVMN

Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress
Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress
EVMN

This Biotech Has Lost 50%-Plus On Just One Drug; Why It's Still Trucking On
This Biotech Has Lost 50%-Plus On Just One Drug; Why It's Still Trucking On
EVMN

Why Is EVMN Stock Down 13% After-Hours?
Why Is EVMN Stock Down 13% After-Hours?
EVMN
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 19.11
- MACD 12/26/9
- -1.44
- EMA 9 of MACD
- -1.35
- MACD histogram
- -0.09
- SMA 50
- $11.18
- Price below SMA 50
- EMA 50
- $10.64
- Price below EMA 50
- SMA 200
- $18.69
- Price below SMA 200
- EMA 200
- $17.27
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 9, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 4 analysts
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.68 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress
Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress
EVMN

Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress
Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress
EVMN

This Biotech Has Lost 50%-Plus On Just One Drug; Why It's Still Trucking On
This Biotech Has Lost 50%-Plus On Just One Drug; Why It's Still Trucking On
EVMN

Why Is EVMN Stock Down 13% After-Hours?
Why Is EVMN Stock Down 13% After-Hours?
EVMN

Evommune scraps eczema drug after trial miss, shares plunge
Evommune scraps eczema drug after trial miss, shares plunge
EVMN

Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis
EVMN

Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights
Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights
EVMN

Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis
Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis
EVMN

EVMN Stock Tanks as Phase IIb Urticaria Study Misses Primary Goal
EVMN Stock Tanks as Phase IIb Urticaria Study Misses Primary Goal
EVMN

Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria
EVMN
News tone: automated (AI) classification of the article's content, not a price prediction.
About Evommune, Inc.
Evommune, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies that target the key drivers of chronic inflammatory diseases. The company’s initial clinical programs center on chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). Chronic inflammation represents a major global healthcare challenge, significantly affecting patients’ quality of life and contributing to the development of life-threatening conditions.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Luis C. Pena | Founder, President, CEO & Director | 1963 |
| Mr. Kyle Carver CPA, M.B.A. | Chief Financial Officer | 1988 |
| Mr. Gregory S. Moss Esq. | Chief Business & Legal Officer, Corporate Secretary and Chief Compliance Officer | 1984 |
| Dr. Eugene Andrew Bauer M.D. | Co-Founder, Chief Medical Officer & Director | 1942 |
| Dr. Jeegar Patel Ph.D. | Chief Scientific Officer | 1978 |
| Ms. Janice Drew M.P.H. | Chief of Development Operations | 1963 |
| Dr. Lou Sehl Ph.D. | Senior Vice President of Technical Operations | — |
| Dr. Daniel J. Burge M.d. | Senior Vice President of Clinical Development | 1962 |
| Mr. J. Mark Jackson M.D. | Senior Vice President of Clinical Development | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Source: third-party data provider, as of October 12, 2026
Technical indicators
- RSI 14
- 19.11
- MACD 12/26/9
- -1.44
- EMA 9 of MACD
- -1.35
- MACD histogram
- -0.09
- SMA 50
- $11.18
- Price below SMA 50
- EMA 50
- $10.64
- Price below EMA 50
- SMA 200
- $18.69
- Price below SMA 200
- EMA 200
- $17.27
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 9, 2026. Technical data, not a recommendation.
Analyst views
4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $21.00
- Average
- $23.67
- High
- $28.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | +2.4 | -18.1 | ||||||||||
| 2026 | +4.6 | +35.2 | -10.2 | +6.2 | -5.2 | -40.1 | -12.2 | +9.2 | -33.8 | -13.3 |



